£3m accelerates new drugs for lung infections in cystic fibrosis
Drug Discovery World
OCTOBER 2, 2024
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections in people with CF.
Let's personalize your content